IP Library Granted Patent US 9,737,593
Granted Patent B2
US 9,737,593 · App. 13/842,782 · Granted Aug 22, 2017

Carbon nanotube compositions and methods of use thereof

Inventors: Tarek M. Fahmy (New Haven, CT); Lisa D. Pfefferle (Branford, CT); Gary L. Haller (Hamden, CT)
Assignee: Yale University
A61K39/00A61K35/17A61K39/0011A61K39/385A61K39/39A61K2039/5158A61K2039/55555A61K2039/6093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,737,593
App. No.
13/842,782
Granted
Aug 22, 2017
Kind
B2
Abstract

Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.

Claims (18)

1. A carbon nanotube bundle comprising

acid washed carbon nanotubes, the nanotubes having bound to or present on the surface

one or more T cell receptor activators selected from the group consisting of antigens bound to WIC molecules and antibodies or fragments thereof that crosslink the T cell receptor/CD3 complex,

one or more T cell costimulatory or T cell adhesion molecules, and

polymeric nanoparticles comprising a cytokine encapsulated therein.

2. The carbon nanotube bundle of claim 1 , wherein the carbon nanotubes are single-walled carbon nanotubes.

3. The carbon nanotube bundle of claim 1 , wherein the one or more T cell receptor activators are non-covalently bound to the carbon nanotubes by adsorption.

4. The carbon nanotube bundle of claim 1 , wherein the carbon nanotubes are treated with acid prior to adsorption of the one or more T cell receptor activators, and further treated with lithium borohydride.

5. The carbon nanotube bundle of claim 1 , wherein the T cell receptor activator is a polyclonal T cell activator.

6. The carbon nanotube bundle of claim 1 , wherein the T cell receptor activator comprises WIC molecules bound to peptide antigens.

7. The carbon nanotube bundle of claim 1 , wherein the cytokine is IL-2.

8. The carbon nanotube bundle of claim 7 , wherein the nanoparticle further comprises ferromagnetic and superparamagnetic materials.

9. The carbon nanotube bundle of claim 7 , wherein the polymer is polylactic acid, polyglycolic acid, or polylactide-co-glycolide.

10. The carbon nanotube bundle of claim 1 , further comprising a magnetic particle.

11. The carbon nanotube bundle of claim 10 , wherein the magnetic particle is bound to or present on the nanotube.

12. The carbon nanotube bundle of claim 11 , wherein the magnetic particle is magnetite.

13. The carbon nanotube bundle of claim 10 , wherein the magnetic particle is selected from the group consisting of ferromagnetic and superparamagnetic materials.

14. The carbon nanotube bundle of claim 1 , wherein the polymer of the nanoparticles is biodegradable.

Assignments (4)
CONFIRMATORY LICENSE Recorded May 10, 2023
From: YALE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 063593/0526 →
CONFIRMATORY LICENSE Recorded Nov 16, 2020
From: YALE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 054439/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2018
From: FADEL, TAREK R.
To: YALE UNIVERSITY
Reel/Frame 044717/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2016
From: FAHMY, TAREK M.; PFEFFERLE, LISA D.; HALLER, GARY
To: YALE UNIVERSITY
Reel/Frame 038202/0760 →
Continuity (3)
Continuation In Part 12933223
Provisional Application 61037798 · Mar 19, 2008
Related Publication 20130216581A1 · Aug 22, 2013